Tonix Pharmaceuticals(NASDAQ) TNXP

Tonix Pharmaceuticals develops treatments for conditions like fibromyalgia and migraines. The company focuses on central nervous system disorders, immunology, rare diseases, and infectious diseases. Tonix has two FDA-approved migraine treatments while advancing clinical trials for other therapies.

Medicine Cabinet

Migraine treatments: FDA-approved Zembrace SymTouch and Tosymra for acute migraine relief.

Fibromyalgia therapy: TNX-102 SL in late-stage development with FDA application submitted.

Immunology portfolio: TNX-1500 antibody targeting organ transplant rejection and autoimmune diseases.

Infectious disease pipeline: Vaccines for COVID-19, smallpox, and monkeypox in development stages.

Rare disease treatments: TNX-2900 being developed for Prader-Willi syndrome.

Strategic Moves

Filed TNX-102 SL New Drug Application in October 2024, with FDA decision expected by August 15, 2025.

Selected manufacturing partners in March 2024 to prepare for potential TNX-102 SL commercial production.

Maintains diverse therapeutic portfolio spanning CNS, immunology, infectious diseases, and rare diseases.

What Makes Tonix Tick

Tonix differentiates itself through a diverse pipeline spanning multiple therapeutic areas including CNS disorders, immunology, infectious diseases, and rare conditions. The company leverages integrated development capabilities to advance innovative programs from clinical trials toward FDA approval and commercialization.

Five Things You Need to Know

Cash and cash equivalents totaled $98.8 million as of December 31, 2024.

Reported GAAP accumulated deficit of $730.7 million as of December 31, 2024.

TNX-102 SL for fibromyalgia represents a critical product for future prospects.

Faces challenge maintaining NASDAQ's minimum $1.00 per share requirement.

Bottom Line

Tonix Pharmaceuticals is advancing a diverse pipeline of clinical-stage candidates while working to commercialize its first major therapy for fibromyalgia. The company's future hinges on regulatory approvals and successfully transitioning from development to revenue generation.